Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581538 | 0.83 | EPHX1 (0.50) | KDM1AEPHX1EPHX2CYP2C19PARP1 | |
| SCHEMBL11942148 | 0.82 | EPHX1 (0.53) | KDM1AEPHX1EPHX2CYP2C19PARP1 | |
| SCHEMBL4131627 | 0.81 | EPHX1 (0.59) | KDM1AEPHX1EPHX2CYP2C19PARP1 | |
| SCHEMBL23490137 | 0.79 | EPHX1 (0.57) | KDM1AEPHX1EPHX2CYP2C19PARP1 | |
| SCHEMBL3581534 | 0.79 | EPHX1 (0.50) | KDM1AEPHX1EPHX2CYP2C19PARP1 | |
| Trifluoroacetic Acid SCHEMBL4513278 | 0.78 | EPHX1 (0.49) | KDM1AEPHX1EPHX2CYP2C19PARP1 | |
| SCHEMBL5758149 | 0.77 | EPHX1 (0.46) | KDM1AEPHX1EPHX2RIPK1 | |
| SCHEMBL13162268 | 0.76 | EPHX1 (0.47) | KDM1AEPHX1EPHX2CYP2C19ALDH1A1 | |
| SCHEMBL13638962 | 0.76 | EPHX1 (0.47) | KDM1AEPHX1EPHX2CYP2C19ALDH1A1 | |
| SCHEMBL4131266 | 0.75 | EPHX1 (0.45) | KDM1AEPHX1EPHX2CYP2C19PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300891-A1 | SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME | INCYTE CORPORATION | 2021-09-30 | — | — | US | disclosed |
| WO-2020047198-A1 | SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME | INCYTE CORPORATION (US) | 2020-03-05 | — | — | WO | disclosed |
| US-20200071289-A1 | SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME | WILMINGTON PHARMATECH | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071289-A1 | SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME | KDM1A, KDM1B, KDM2A | KDM1A 1/4885EPHX1 1897/4885EPHX2 2868/4885 |
| US-20210300891-A1 | SALTS OF AN LSD1 INHIBITOR AND PROCESSES FOR PREPARING THE SAME | KDM1A, KDM1B, KDM2A | KDM1A 1/4885EPHX1 1897/4885EPHX2 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.